Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus.

Adult Child Consensus Humans Research Retrospective Studies Stevens-Johnson Syndrome / diagnosis

Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
09 2021
Historique:
accepted: 25 02 2021
pubmed: 4 3 2021
medline: 21 9 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Supportive care is the cornerstone of management of adult and paediatric Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, consensus on the modalities of supportive care is lacking. Our aim in this international multicentric Delphi exercise was to establish a multidisciplinary expert consensus to standardize recommendations regarding supportive care in the acute phase of SJS/TEN. Participants were sent a survey via the online tool SurveyMonkey, consisting of 103 statements organized into 11 topics: multidisciplinary team composition, suspect drug management, infection prevention, fluid resuscitation and prevention of hypothermia, nutritional support, pain and psychological distress management, management of acute respiratory failure, local skincare, ophthalmological management, management of other mucosa, and additional measures. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). The results were analysed according to the RAND/UCLA Appropriateness Method. Forty-five participants from 13 countries (on three continents) participated. After the first round, a consensus was obtained for 82.5% of the 103 initially proposed statements. After the second round, a final consensus was obtained for 102 statements. We have reached an international Delphi-based consensus on best supportive care practice for SJS/TEN. Our expert consensus should help guide physicians in treating patients with SJS/TEN and thereby improve short-term prognosis and the risk of sequelae.

Sections du résumé

BACKGROUND
Supportive care is the cornerstone of management of adult and paediatric Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, consensus on the modalities of supportive care is lacking.
OBJECTIVES
Our aim in this international multicentric Delphi exercise was to establish a multidisciplinary expert consensus to standardize recommendations regarding supportive care in the acute phase of SJS/TEN.
METHODS
Participants were sent a survey via the online tool SurveyMonkey, consisting of 103 statements organized into 11 topics: multidisciplinary team composition, suspect drug management, infection prevention, fluid resuscitation and prevention of hypothermia, nutritional support, pain and psychological distress management, management of acute respiratory failure, local skincare, ophthalmological management, management of other mucosa, and additional measures. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). The results were analysed according to the RAND/UCLA Appropriateness Method.
RESULTS
Forty-five participants from 13 countries (on three continents) participated. After the first round, a consensus was obtained for 82.5% of the 103 initially proposed statements. After the second round, a final consensus was obtained for 102 statements.
CONCLUSIONS
We have reached an international Delphi-based consensus on best supportive care practice for SJS/TEN. Our expert consensus should help guide physicians in treating patients with SJS/TEN and thereby improve short-term prognosis and the risk of sequelae.

Identifiants

DOI: 10.1111/bjd.19893 PMID: 33657677
pubmed: 33657677
doi: 10.1111/bjd.19893
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-626

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 British Association of Dermatologists.

Références

Kuijper EC, French LE, Tensen CP et al. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol 2020; 34:1957-71.
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390:1996-2011.
Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35-44.
Sekula P, Dunant A, Mockenhaupt M et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133:1197-204.
Micheletti RG, Chiesa-Fuxench Z, Noe MH et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicentre retrospective study of 377 adult patients from the United States. J Invest Dermatol 2018; 138:2315-21.
Bettuzzi T, Penso L, de Prost N et al. Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. Br J Dermatol 2020; 182:247-8.
Chaby G, Maldini C, Haddad C et al. Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate. Br J Dermatol 2020; 182:618-24.
Sassolas B, Haddad C, Mockenhaupt M et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60-8.
Chaby G, Ingen-Housz-Oro S, De Prost N et al. Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients’ characteristics. J Am Acad Dermatol 2019; 80:1453-5.
Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-53.
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol 2016; 136:1387-97.
Ingen-Housz-Oro S, Alves A, Colin A et al. Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. Br J Dermatol 2020; 182:916-26.
Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol 2017; 177:924-35.
Heng YK, Lee HY, Roujeau J-C. Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol 2015; 173:1250-4.
Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019-24.
Bequignon E, Duong TA, Sbidian E et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol 2015; 151:302-7.
Gueudry J, Roujeau J-C, Binaghi M et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145:157-62.
Gendreau S, Amiot A, Le Baleur Y et al. Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. Br J Dermatol 2019; 180:1234-5.
Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome): more than ‘acute skin failure’. Intensive Care Med 1992; 18:4-5.
Lecadet A, Woerther P-L, Hua C et al. Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: a retrospective observational cohort study of 98 cases. J Am Acad Dermatol 2019; 81:342-7.
Koh HK, Chai ZT, Tay HW et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients. J Am Acad Dermatol 2019; 81:686-93.
de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42:118-28.
Lebargy F, Wolkenstein P, Gisselbrecht M et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23:1237-44.
Ingen-Housz-Oro S, Duong T-A, Bensaid B et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; Protocole National de Diagnostic et de Soins). Orphanet J Rare Dis 2018; 13:56.
Kaffenberger BH, Rosenbach M. Toxic epidermal necrolysis and early transfer to a regional burn unit: is it time to reevaluate what we teach? J Am Acad Dermatol 2014; 71:195-6.
Creamer D, Walsh SA, Dziewulski P et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174:1194-227.
Traikia C, Hua C, Le Cleach L et al. Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016. Br J Dermatol 2020; 182:900-6.
Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-9.
Wang C-W, Yang L-Y, Chen C-B et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 2018; 128:985-96.
Ingen-Housz-Oro S, Duong T-A, de Prost N et al. [Treatment of severe cutaneous adverse drug reactions]. Ann Dermatol Venereol 2018; 145:454-64 (in French).
White KD, Abe R, Ardern-Jones M et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract 2018; 6:38-69.
Zimmermann S, Sekula P, Venhoff M et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2017; 153:514-22.
McPherson T, Exton LS, Biswas S et al. British Association of Dermatologists’ guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol 2019; 181:37-54.
Jandhyala R. Delphi, non-RAND modified Delphi, RAND of UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res Opin 2020; 36:1873-87.
Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136:323-7.
Ingen-Housz-Oro S, Le Floch R, Alves A et al. Carrying out local care for epidermal necrolysis: survey of practices. J Eur Acad Dermatol Venereol 2021; 35:e155-e157.
Singer M, Deutschman CS, Seymour CW et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801-10.
Inamadar AC, Palit A. Acute skin failure: concept, causes, consequences and care. Indian J Dermatol Venereol Leprol 2005; 71:379-85.
Hefez L, Zaghbib K, Sbidian E et al. Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. Br J Dermatol 2019; 180:1206-13.
Castillo B, Vera N, Ortega-Loayza AG, Seminario-Vidal L. Reply to: ‘Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: an unmet need’. J Am Acad Dermatol 2018; 79:e89.
Lee HY. Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: an unmet need. J Am Acad Dermatol 2018; 79:e87-e88.
Hajj C, Ezzedine K, Thorel D et al. Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae. Br J Dermatol 2019; 181:421-2.
Thorel D, Ingen-Housz-Oro S, Royer G et al. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: French national audit of practices, literature review, and consensus agreement. Orphanet J Rare Dis 2020; 15:259.
Seminario-Vidal L, Kroshinsky D, Malachowski SJ et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol 2020; 82:1553-67.

Auteurs

M-C Brüggen (MC)

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
ORCID: 0000-0002-8607-6254

S T Le (ST)

Department of Dermatology, University of California, Davis, Sacramento, CA, USA.

S Walsh (S)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatology, King's College Hospital, London, UK.

A Toussi (A)

Department of Dermatology, University of California, Davis, Sacramento, CA, USA.

N de Prost (N)

Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.

A Ranki (A)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

B Didona (B)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
First Dermatology Division, Institute Dermopatico dell'Immacolata (I.D.I.) - IRCCS, Via Monti di Creta 104, Rome, 00167, Italy.

A Colin (A)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.

B Horváth (B)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

E Brezinova (E)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatovenereology, St Ann's University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

B Milpied (B)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Department of Dermatology, CHU Bordeaux, Bordeaux, France.

C Moss (C)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Birmingham Children's Hospital and University of Birmingham, Birmingham, UK.

C Bodemer (C)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Department of Dermatology, AP-HP, Necker Hospital, Paris, France.

D Meyersburg (D)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, Austria.

C Salavastru (C)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

G-S Tiplica (GS)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

E Howard (E)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Birmingham Children's Hospital and University of Birmingham, Birmingham, UK.

E Bequignon (E)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Otorhinolaryngology and Head and Neck Surgery, AP-HP, Henri Mondor Hospital, Créteil, France.

J N Bouwes Bavinck (JN)

Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.

J Newman (J)

Macmillan Skin Cancer CNS, Normanby Building, Denmark Hill, London, UK.

J Gueudry (J)

Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Ophthalmology Department, Hospital Charles Nicolle, EA7510, UFR Santé, Rouen University, Rouen, France.

M Nägeli (M)

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

K Zaghbib (K)

Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Department of Psychiatry, AP-HP, Henri Mondor-Albert Chenevier Hospitals, Cr, France.

K Pallesen (K)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens, Aarhus, Denmark.

A Bygum (A)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Clinical Institute, University of Southern Denmark, Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.

P Joly (P)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Department of Dermatology, CHU Charles, Nicolle, Rouen, France.

P Wolkenstein (P)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.

S-L Chua (SL)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.

R Le Floch (R)

Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Réanimation Chirurgicale et des Brûlés, PTMC, CHU Nantes, Nantes, France.

N H Shear (NH)

Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

C-Y Chu (CY)

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

N Hama (N)

Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

R Abe (R)

Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

W-H Chung (WH)

Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

T Shiohara (T)

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.

M Ardern-Jones (M)

Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

P Romanelli (P)

Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.

E J Phillips (EJ)

Department of Medicine & Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.

R S Stern (RS)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

J Cotliar (J)

Science 37, Los Angeles, CA, USA.

R G Micheletti (RG)

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

A Brassard (A)

Department of Dermatology, University of California, Davis, Sacramento, CA, USA.

J T Schulz (JT)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

R P Dodiuk-Gad (RP)

Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

A R Dominguez (AR)

Department of Dermatology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

A S Paller (AS)

Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

L Seminario-Vidal (L)

Department of Dermatology, University of South Florida, Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.

A Mostaghimi (A)

Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

M H Noe (MH)

Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

S Worswick (S)

Keck-USC School of Medicine, Los Angeles, CA, USA.

D Tartar (D)

Department of Dermatology, University of California, Davis, Sacramento, CA, USA.

R Sheridan (R)

Burn Surgery Service, Shriners Burns Hospital, Sumner Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

B H Kaffenberger (BH)

Division of Dermatology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA.

K Shinkai (K)

Department of Dermatology, University of California, San Francisco, CA, USA.

E Maverakis (E)

Department of Dermatology, University of California, Davis, Sacramento, CA, USA.

L E French (LE)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Department of Dermatology and Allergy, University Hospital of Munich, LMU, Munich, Germany.

S Ingen-Housz-Oro (S)

ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
Universit, EpiDermE, Créteil, France.
ORCID: 0000-0002-5383-7096

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Supportive care in the acute phase of...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Supportive care in the acute phase of...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Supportive care in the acute phase of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Supportive care in the acute phase of...
questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Supportive care in the acute phase of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Supportive care in the acute phase of...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Hypersensibilité médicamenteuse › Toxidermies › Syndrome de Stevens-Johnson › Supportive care in the acute phase of...